Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

Pages

423 results
8:18 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
10:53 AM, Aug 03, 2018  |  BC Week In Review | Company News  |  Deals

Kyowa, Ultragenyx sell Priority Review voucher for $80.6M

Crysvita burosumab-twza to treat X-linked hypophosphatemia. Crysvita is a recombinant human IgG1 mAb against fibroblast growth factor
8:35 AM, Jul 27, 2018  |  BC Week In Review | Company News  |  Deals

MedPacto partners with AZ, Merck for combo trials

expects to finish the trials within two years. Vactosertib is an oral inhibitor of transforming growth factor
10:21 AM, Jul 20, 2018  |  BC Week In Review | Company News  |  Deals

Roivant's China biotech reveals pipeline, pair of deals

its pipeline, and Sinovant began operations last year. The newco's late stage assets include fibroblast growth factor
12:32 PM, Jul 13, 2018  |  BC Week In Review | Company News  |  Deals

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550 million...
10:25 AM, Jun 29, 2018  |  BC Week In Review | Company News  |  Deals

China's Everest gets rights to Novartis' FGFR4 inhibitor

FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN). The deal marks the second in-licensing of a fibroblast growth factor
9:47 AM, Jun 08, 2018  |  BC Week In Review | Company News  |  Deals

Cstone gets Chinese rights to Blueprint clinical pipeline

cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117) exon 17 mutations and platelet derived growth factor
in April (see BioCentury, April 20) . BLU-554 is an isoform selective inhibitor of fibroblast growth factor
12:08 PM, Apr 20, 2018  |  BC Week In Review | Company News  |  Deals

Basilea gains rights to ArQule's derazantinib

087) outside of Taiwan and China, including Hong Kong and Macau. Derazantinib is a pan-fibroblast growth factor
single- to double-digit royalties. Derazantinib is in a pivotal Phase II trial to treat keratinocyte growth factor
11:00 AM, Apr 13, 2018  |  BC Week In Review | Company News  |  Deals

Oncology Venture licenses dovitinib from Novartis

Oncology Venture Sweden AB (AktieTorget:OV) exercised its option and will receive exclusive, worldwide rights to develop and commercialize dovitinib (TKI258) from Novartis AG (NYSE:NVS; SIX:NOVN). Novartis will receive an upfront payment and is eligible for development...
12:00 PM, Feb 16, 2018  |  BC Week In Review | Company News  |  Deals

ArQule grants Roivant rights to derazantinib in China and Taiwan

also eligible for regulatory and commercial milestones, as well as royalties. Derazantinib is a fibroblast growth factor
FGF) receptor (FGFR) inhibitor in Phase III testing to treat keratinocyte growth factor (KGF) receptor (KGFR; FGFR2 …

Pages